GlassScriptPhysician profile
Sushma N Pandrangi
NPI 1306981014
$676.78
in general payments reported to CMS, 2019-2025
17 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $53.07 · 2021: $127 · 2022: $50.38 · 2023: $116 · 2024: $35.98 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $238 · Education: $78.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $238.35 |
| Education | $78.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $205.69 | 2019-2025 | Velphoro |
| Travere Therapeutics, INC. | $73.60 | 2024-2025 | Filspari |
| Vifor Pharma, INC. | $52.14 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $44.18 | 2022-2023 | Acthar |
| Glaxosmithkline, LLC. | $39.43 | 2021-2025 | Benlysta |
| Akebia Therapeutics INC | $37.51 | 2021 | |
| Amgen INC. | $30.40 | 2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $27.25 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $21.82 | 2023 | Ultomiris |
| Opko Pharmaceuticals, LLC | $21.05 | 2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $16.36 | 2025 | Yorvipath |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.05 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushma Pandrangi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.